期刊文献+

血管生成抑制剂治疗肺癌进展 被引量:1

下载PDF
导出
摘要 近年来,新生血管形成在肺癌的发展、转移和转归中的作用备受关注。靶向血管生成各环节的血管生成抑制剂不断出现,联合化疗正逐渐改变肺癌治疗局面。
作者 操乐杰
出处 《世界临床药物》 CAS 2004年第5期288-291,296,共5页 World Clinical Drug
  • 相关文献

参考文献1

  • 1J.W. Mall,A.W. Philipp,W. Mall,C. Pollmann. Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy[J] 2002,Angiogenesis(1-2):11~13 被引量:1

同被引文献19

  • 1毛友生,高燕宁,赫捷,张德超,程书钧.肺癌分子生物学特性与转移和预后的关系[J].中华肿瘤杂志,2006,28(8):632-634. 被引量:60
  • 2郭斌,袁戈.魟鱼软骨多糖对小鼠Lewis肺癌的作用及分子机制探讨[J].辽宁中医杂志,2007,34(1):110-112. 被引量:4
  • 3Bikfalvi A,Klein S,Pintucci G,et al.Biological roles of fibroblast growth factor-2[J].Endocr Rev,1997,18(1):26-45. 被引量:1
  • 4Presta M,Dell'Era P,Mitola S,et al.Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis[J].Cytokine Growth Factor Rev,2005,16(2):159-178. 被引量:1
  • 5Cox G,Jones JL,Walker RA,et al.Angiogenesis and nonsmall cell lung cancer[J].Lung Cancer,2000,27(2):81-100. 被引量:1
  • 6Weidner N.Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors[J].Breast Cancer Res Treat,1995,36(2):169-180. 被引量:1
  • 7Joensuu H,Anttonen A,Eriksson M,et al.Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer[J].Cancer Res,2002,62(18):5210-5217. 被引量:1
  • 8Kuhn H,KǒpffC,Konrad J,et al.Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines[J].Lung Cancer,2004,44(22):167-174. 被引量:1
  • 9Pardo OE,Wellbrock C,Khanzada UK,et al.FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKC ε,B-Raf and S6K2[J].EMBO J,2006,25(13):3078-3088. 被引量:1
  • 10Pardo OE,Latigo J,Jeffery RE,et al.The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo[J].Cancer Res,2009,69(22):8645-8651. 被引量:1

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部